Naporafenib + Dacarbazine + Temozolomide + Trametinib
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic NRAS-mutant Melanoma
Conditions
Advanced or Metastatic NRAS-mutant Melanoma
Trial Timeline
Apr 29, 2024 → Dec 1, 2028
NCT ID
NCT06346067About Naporafenib + Dacarbazine + Temozolomide + Trametinib
Naporafenib + Dacarbazine + Temozolomide + Trametinib is a phase 3 stage product being developed by Erasca for Advanced or Metastatic NRAS-mutant Melanoma. The current trial status is active. This product is registered under clinical trial identifier NCT06346067. Target conditions include Advanced or Metastatic NRAS-mutant Melanoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced or Metastatic NRAS-mutant Melanoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06346067 | Phase 3 | Active |
Competing Products
20 competing products in Advanced or Metastatic NRAS-mutant Melanoma